U.S. markets close in 1 hour 24 minutes
  • S&P 500

    3,755.76
    -27.52 (-0.73%)
     
  • Dow 30

    29,994.32
    -279.55 (-0.92%)
     
  • Nasdaq

    11,106.66
    -41.98 (-0.38%)
     
  • Russell 2000

    1,754.59
    -8.11 (-0.46%)
     
  • Crude Oil

    88.40
    +0.64 (+0.73%)
     
  • Gold

    1,721.20
    +0.40 (+0.02%)
     
  • Silver

    20.69
    +0.15 (+0.71%)
     
  • EUR/USD

    0.9811
    -0.0074 (-0.75%)
     
  • 10-Yr Bond

    3.8090
    +0.0500 (+1.33%)
     
  • GBP/USD

    1.1177
    -0.0145 (-1.28%)
     
  • USD/JPY

    144.9910
    +0.3810 (+0.26%)
     
  • BTC-USD

    20,106.47
    -83.60 (-0.41%)
     
  • CMC Crypto 200

    457.35
    -5.77 (-1.25%)
     
  • FTSE 100

    6,997.27
    -55.35 (-0.78%)
     
  • Nikkei 225

    27,311.30
    +190.80 (+0.70%)
     

Strong week for AVEO Pharmaceuticals (NASDAQ:AVEO) shareholders doesn't alleviate pain of five-year loss

·3 min read

This week we saw the AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) share price climb by 20%. But will that heal all the wounds inflicted over 5 years of declines? Unlikely. Five years have seen the share price descend precipitously, down a full 77%. It's true that the recent bounce could signal the company is turning over a new leaf, but we are not so sure. The real question is whether the business can leave its past behind and improve itself over the years ahead.

While the last five years has been tough for AVEO Pharmaceuticals shareholders, this past week has shown signs of promise. So let's look at the longer term fundamentals and see if they've been the driver of the negative returns.

View our latest analysis for AVEO Pharmaceuticals

AVEO Pharmaceuticals isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size.

Over five years, AVEO Pharmaceuticals grew its revenue at 41% per year. That's well above most other pre-profit companies. So on the face of it we're really surprised to see the share price has averaged a fall of 12% each year, in the same time period. It could be that the stock was over-hyped before. We'd recommend carefully checking for indications of future growth - and balance sheet threats - before considering a purchase.

You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values).

earnings-and-revenue-growth
earnings-and-revenue-growth

We consider it positive that insiders have made significant purchases in the last year. Even so, future earnings will be far more important to whether current shareholders make money. You can see what analysts are predicting for AVEO Pharmaceuticals in this interactive graph of future profit estimates.

A Different Perspective

While the broader market lost about 19% in the twelve months, AVEO Pharmaceuticals shareholders did even worse, losing 29%. Having said that, it's inevitable that some stocks will be oversold in a falling market. The key is to keep your eyes on the fundamental developments. Regrettably, last year's performance caps off a bad run, with the shareholders facing a total loss of 12% per year over five years. Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Case in point: We've spotted 1 warning sign for AVEO Pharmaceuticals you should be aware of.

If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: insiders have been buying them).

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.